FUSNFusion Pharmaceuticals Inc.

Nasdaq fusionpharma.com


$ 21.40 $ -0.02 (-0.09 %)    

Thursday, 09-May-2024 14:11:35 EDT
QQQ $ 440.74 $ 0.28 (0.06 %)
DIA $ 393.14 $ 3.06 (0.78 %)
SPY $ 519.11 $ 1.67 (0.32 %)
TLT $ 90.54 $ 0.50 (0.56 %)
GLD $ 216.06 $ 1.36 (0.63 %)
$ 21.4
$ 21.42
$ 0.00 x 0
$ 21.40 x 100
$ 21.39 - $ 21.43
$ 2.31 - $ 21.58
563,195
na
1.79B
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fusion-pharmaceuticals-q1-2024-gaap-eps-040-misses-037-estimate

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate...

Core News & Articles

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuca...

 td-cowen-downgrades-fusion-pharmaceuticals-to-hold

TD Cowen analyst Tara Bancroft downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.

 astrazeneca-hikes-annual-dividend-by-7-just-before-vote-on-its-ceos-pay-package-boost

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CE...

 astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in-weight-loss-race

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. ...

 rbc-capital-reiterates-sector-perform-on-fusion-pharmaceuticals-maintains-21-price-target

RBC Capital analyst Gregory Renza reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Sector Perform and maintains $21 pr...

 wedbush-reiterates-neutral-on-fusion-pharmaceuticals-maintains-24-price-target

Wedbush analyst David Nierengarten reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Neutral and maintains $24 price ta...

 fusion-pharmaceuticals-q4-2023-gaap-eps-039-misses-034-estimate

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate...

 raymond-james-downgrades-fusion-pharmaceuticals-to-market-perform

Raymond James analyst Rahul Sarugaser downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Strong Buy to Market Perform.

 b-riley-securities-downgrades-fusion-pharmaceuticals-to-neutral-raises-price-target-to-23

B. Riley Securities analyst Yuan Zhi downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Neutral and raises the pric...

 truist-securities-downgrades-fusion-pharmaceuticals-to-hold-raises-price-target-to-21-report-released-on-19th-march-2024

Truist Securities analyst Nicole Germino downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the pri...

 rbc-capital-downgrades-fusion-pharmaceuticals-to-sector-perform-raises-price-target-to-21

RBC Capital analyst Gregory Renza downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Sector Perform and rais...

 jonestrading-downgrades-fusion-pharmaceuticals-to-hold

JonesTrading analyst Justin Walsh downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.

 nasdaq-turns-higher-caleres-posts-upbeat-q4-results

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow...

 why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION